Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
06:50am, Monday, 02'nd Jun 2025
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 b
MAINZ, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
12:46pm, Thursday, 29'th May 2025
Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock?
10:21am, Thursday, 29'th May 2025
BMY slides 20.7% in 3 months despite strong Q1 and raised outlook, as generic pressure and pipeline setbacks weigh on investor sentiment.
Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
06:50pm, Wednesday, 28'th May 2025
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
10:07am, Wednesday, 28'th May 2025
Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Wednesday, 28'th May 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
06:59am, Wednesday, 28'th May 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications.
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
04:42pm, Tuesday, 27'th May 2025
Bristol-Myers Squibb Company appears deeply undervalued, despite business headwinds and revenue declines from legacy products facing generic competition. The market is already pricing in revenue and E
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
12:16pm, Tuesday, 27'th May 2025
I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, an
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
09:14am, Tuesday, 27'th May 2025
Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EP
When It Rains Gold, Put Out The Bucket: 2 Wonderful Income Bargains
11:45am, Monday, 26'th May 2025
Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong pr
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Monday, 26'th May 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Avoid These Dividend Disasters Before It's Too Late
08:15am, Friday, 23'rd May 2025
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
